Darzalex is approved for MM patients who have received at least three prior treatments. In the 7 months since approval, Darzalex has captured 24% share of the 3 rd line + segment , unchanged from the previous month. In 3rd line+, Revlimid remained the market leader with 31% share, down from 39% share in April, continuing to reflected combination use with both established agents – i.e. Kyprolis – and emerging agents – i.e. Empliciti. Kyprolis share rose from 24% in April to 26% in May. We estimate 2016 US Darzalex sales of $437MM, which is consistent with JNJ’s partner Genmab’s expectation of $400- $450MM. For comparison, Kyprolis generated US sales of $71MM in 2013, its first year on the market, and global sales of $512MM in 2015. Although only approved for 3rd line+ so far, JNJ is studying Darzalex for earlier uses . In recent months, JNJ stopped early two Phase 3 studies of Darzalex combination studies for relapsed/refractory (R/R) MM based on positive interim analysis, which showed a PFS (progress-free survival) benefit. Data from both studies – Castor (Darzalex plus Velcade/dexamethasone) and Pollux (Darzalex plus Revlimid/dexamethasone) – were presented at major medical meetings in June.
We made more in one year than you did after being on the market for 3 years. Such little kids Amgen SUPPORTIVE CARE
We made more in one year than you did after being on the market for 3 years. Such little kids Amgen SUPPORTIVE CARE